JP2017528461A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528461A5
JP2017528461A5 JP2017512983A JP2017512983A JP2017528461A5 JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5 JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
alkyl
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049225 external-priority patent/WO2016040508A1/en
Publication of JP2017528461A publication Critical patent/JP2017528461A/ja
Publication of JP2017528461A5 publication Critical patent/JP2017528461A5/ja
Pending legal-status Critical Current

Links

JP2017512983A 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物 Pending JP2017528461A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048763P 2014-09-10 2014-09-10
US62/048,763 2014-09-10
US201562146804P 2015-04-13 2015-04-13
US62/146,804 2015-04-13
PCT/US2015/049225 WO2016040508A1 (en) 2014-09-10 2015-09-09 Substituted pyrrolidine carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017528461A JP2017528461A (ja) 2017-09-28
JP2017528461A5 true JP2017528461A5 (enExample) 2018-10-18

Family

ID=55459531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512983A Pending JP2017528461A (ja) 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物

Country Status (6)

Country Link
US (2) US20170247326A1 (enExample)
EP (1) EP3193609A4 (enExample)
JP (1) JP2017528461A (enExample)
AU (1) AU2015315177A1 (enExample)
CA (1) CA2960277A1 (enExample)
WO (1) WO2016040508A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015315180A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamides as irreversible SMYD inhibitors
BR112017004612A2 (pt) 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
US10106510B2 (en) 2014-09-10 2018-10-23 Epizyme, Inc. Substituted isoxazoles for treating cancer
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428493A (en) * 1973-05-02 1976-03-17 Science Union & Cie Heterocyclic amides processes for their preparation and pharma ceutical compositions containing them
JPS52128368A (en) * 1976-04-15 1977-10-27 Yamanouchi Pharmaceut Co Ltd Novel carboxylic acid amide derivatives and their preparation
GR66581B (enExample) * 1978-02-21 1981-03-27 Delalande Sa
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
DE10148290A1 (de) * 2001-09-29 2003-04-17 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2004080982A1 (en) * 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
BRPI0408365B8 (pt) * 2003-03-14 2021-05-25 Avidex Ltd compostos heterocíclicos de imunomodulação
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
AR049333A1 (es) * 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2006086609A2 (en) * 2005-02-10 2006-08-17 Axys Pharmaceuticals, Inc. Inhibitors of tryptase
EP1869012A1 (en) * 2005-04-05 2007-12-26 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
CN101160301B (zh) * 2005-04-12 2012-03-28 索尔瓦药物有限公司 氨基烷基-酰胺基甲基-取代的2-(4-磺酰基氨基)-3-羟基-3,4-二氢-2h-色烯-6-基衍生物以及它们作为钾通道阻断剂的用途
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
BRPI0717314A2 (pt) * 2006-10-24 2014-01-21 Janssen Pharmaceutica Nv Derivados de ácido tetra-hidro-naftaleno-1-carboxílico inibidores de mtp
EP1975165A1 (de) * 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
CN101778838A (zh) * 2007-05-24 2010-07-14 惠氏有限责任公司 作为组胺-3拮抗剂的氮杂环基苯甲酰胺衍生物
AU2008279759A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US8518911B2 (en) * 2008-08-05 2013-08-27 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyridines as MARK inhibitors
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
MX359651B (es) * 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.

Similar Documents

Publication Publication Date Title
JP2017528461A5 (enExample)
JP2017538659A5 (enExample)
JP2017511801A5 (enExample)
AU2017221802B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2017528464A5 (enExample)
US9546156B2 (en) N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN111170999B (zh) Egfr抑制剂及其制备和应用
US9981959B2 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
JP5256047B2 (ja) ピロロ[3,2−c]ピリジン−4−オン2−インドリノン(indolinone)プロテインキナーゼ阻害剤
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2017528460A5 (enExample)
JP2017538659A (ja) Smyd阻害剤
EP3033342A1 (en) Annelated pyrroles and their use as crac inhibitors
US20160272592A1 (en) N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP2017528461A (ja) 置換ピロリジンカルボキサミド化合物
JP2009539878A5 (enExample)
JP2017527577A (ja) 置換ピロリジン化合物
JP2017527576A5 (enExample)
US20230095520A1 (en) Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
CN117396468A (zh) 作为ron抑制剂的新型吡啶衍生化合物
EP3262044A1 (en) Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
WO2014034898A1 (ja) ピリジン誘導体及び医薬
JP7768592B2 (ja) 医薬化合物